Envafolimab plus chemotherapy and simvastatin for advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (envafolimab) combined with standard chemotherapy and a common cholesterol medicine (simvastatin) for advanced bile duct and gallbladder cancer. The goal is to see if this combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have an advanced bile duct or gallbladder cancer that cannot be removed with surgery
- Have not received prior treatment for advanced disease, or had surgery or chemotherapy more than 6 months ago before the cancer returned
- Be in overall good health (able to do daily activities) with acceptable organ function
- Not have active autoimmune disease, severe allergies to study drugs, or psychiatric conditions that interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug called envafolimab for people with advanced bile duct or gallbladder cancer. The goal is to see if it can help shrink tumors or slow the disease.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy (gemcitabine and cisplatin), and a cholesterol-lowering drug (simvastatin) for advanced bile duct or gallbladder cancer that cannot be removed by surgery. It aims to see if the addition of simvastatin improves treatment outcomes.
This trial tests a combination of two medications (envafolimab and surufatinib) plus a procedure that uses heat to destroy cancer cells inside the bile ducts. It is for people with bile duct or gallbladder cancer that cannot be removed surgically and who are not candidates for or do not want chemotherapy.
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.